2.325
price down icon3.93%   -0.095
after-market アフターアワーズ: 2.34 0.015 +0.65%
loading
前日終値:
$2.42
開ける:
$2.45
24時間の取引高:
5.22M
Relative Volume:
1.66
時価総額:
$506.62M
収益:
$35.54M
当期純損益:
$-59.14M
株価収益率:
-6.3926
EPS:
-0.3637
ネットキャッシュフロー:
$-80.19M
1週間 パフォーマンス:
-9.18%
1か月 パフォーマンス:
-29.33%
6か月 パフォーマンス:
-47.04%
1年 パフォーマンス:
-31.62%
1日の値動き範囲:
Value
$2.32
$2.45
1週間の範囲:
Value
$2.32
$2.65
52週間の値動き範囲:
Value
$2.32
$8.21

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
名前
Cytomx Therapeutics Inc
Name
セクター
Healthcare (1051)
Name
電話
650.515.3185
Name
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
職員
69
Name
Twitter
@cytomxinc
Name
次回の収益日
2026-11-05
Name
最新のSEC提出書
Name
CTMX's Discussions on Twitter

Compare CTMX vs VRTX, MRNA, REGN, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CTMX icon
CTMX
Cytomx Therapeutics Inc
2.325 506.62M 35.54M -59.14M -80.19M -0.3637
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
485.22 122.98B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
216.25 86.33B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.12 77.54B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
802.64 50.47B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
188.44 40.39B 742.00K -1.37B -1.07B -7.0731

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-05-19 開始されました Wolfe Research Outperform
2026-03-16 アップグレード JP Morgan Neutral → Overweight
2026-01-20 開始されました Guggenheim Buy
2025-09-22 開始されました Cantor Fitzgerald Overweight
2025-09-17 再開されました Barclays Overweight
2025-07-31 開始されました Oppenheimer Outperform
2025-05-15 アップグレード H.C. Wainwright Neutral → Buy
2025-04-14 再開されました Piper Sandler Overweight
2024-05-28 アップグレード Piper Sandler Neutral → Overweight
2024-05-09 アップグレード Wedbush Neutral → Outperform
2024-05-06 アップグレード Jefferies Hold → Buy
2024-04-22 アップグレード JP Morgan Underweight → Neutral
2022-11-14 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-07-07 ダウングレード Jefferies Buy → Hold
2022-07-07 ダウングレード Mizuho Buy → Neutral
2022-07-07 ダウングレード Piper Sandler Overweight → Neutral
2022-07-07 ダウングレード Wedbush Outperform → Neutral
2022-06-24 開始されました BMO Capital Markets Outperform
2022-01-18 アップグレード Barclays Underweight → Overweight
2021-11-15 開始されました BTIG Research Buy
2021-05-28 ダウングレード Barclays Equal Weight → Underweight
2021-03-29 開始されました JP Morgan Overweight
2021-03-23 アップグレード Jefferies Hold → Buy
2020-09-22 ダウングレード Guggenheim Buy → Neutral
2020-06-01 ダウングレード Jefferies Buy → Hold
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-03-24 アップグレード Wedbush Neutral → Outperform
2020-03-04 開始されました Barclays Equal Weight
2019-11-20 開始されました Guggenheim Buy
2019-11-11 ダウングレード Wedbush Outperform → Neutral
2019-06-13 開始されました Mizuho Buy
2019-05-14 開始されました Cantor Fitzgerald Overweight
2019-03-11 開始されました Barclays Overweight
2018-11-26 開始されました Piper Jaffray Overweight
2018-10-15 開始されました Goldman Neutral
2018-09-13 開始されました H.C. Wainwright Buy
2018-06-01 開始されました SunTrust Buy
2018-01-05 開始されました Citigroup Buy
2017-09-08 開始されました Wedbush Outperform
2017-03-27 開始されました H.C. Wainwright Buy
2017-03-02 開始されました Instinet Buy
2017-01-03 ダウングレード Oppenheimer Outperform → Perform
2015-11-02 開始されました Oppenheimer Outperform
すべてを表示

Cytomx Therapeutics Inc (CTMX) 最新ニュース

pulisher
Oct 05, 2026

CytomX outlines cancer strategy. CytomX Therapeutics stock trades ahead of November 5 results - AD HOC NEWS

Oct 05, 2026
pulisher
Oct 02, 2026

Cytomx Therapeutics Stock Price Forecast. Should You Buy CTMX? - StockInvest.us

Oct 02, 2026
pulisher
Oct 02, 2026

Cytomx Thera (CTMX-Q) Stock Price and News - The Globe and Mail

Oct 02, 2026
pulisher
Sep 24, 2026

CytomX Therapeutics (CTMX) Short Interest & Short Float | Updated Sep 2026 - marketbeat.com

Sep 24, 2026
pulisher
Sep 22, 2026

CytomX Therapeutics (NasdaqGS:CTMX) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 22, 2026
pulisher
Sep 18, 2026

CytomX Therapeutics Inc (6C1) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks

Sep 18, 2026
pulisher
Sep 10, 2026

CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare ConferenceSlideshow (NASDAQ:CTMX) 2026-09-10 - Seeking Alpha

Sep 10, 2026
pulisher
Sep 09, 2026

CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com South Africa

Sep 09, 2026
pulisher
Sep 09, 2026

CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com Australia

Sep 09, 2026
pulisher
Sep 09, 2026

CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com Nigeria

Sep 09, 2026
pulisher
Sep 09, 2026

CytomX at cantor healthcare conference: pipeline gains, safety test ahead - investing.com

Sep 09, 2026
pulisher
Sep 09, 2026

CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com India

Sep 09, 2026
pulisher
Sep 08, 2026

CytomX at Wells Fargo conference: epcam bet and cash strength - investing.com

Sep 08, 2026
pulisher
Sep 06, 2026

CTMXCytomX Therapeutics Inc Revenue Breakdown - Finviz

Sep 06, 2026
pulisher
Sep 01, 2026

CytomX Therapeutics to Present at Upcoming September Investor Conferences - Stock Titan

Sep 01, 2026
pulisher
Sep 01, 2026

CytomX Therapeutics to Present at Upcoming September Investor Conferences - finance.yahoo.com

Sep 01, 2026
pulisher
Aug 27, 2026

FDA grants fast track status to CytomX’s colorectal cancer drug By Investing.com - Investing.com Canada

Aug 27, 2026
pulisher
Aug 27, 2026

FDA grants fast track status to CytomX’s colorectal cancer drug - Investing.com India

Aug 27, 2026
pulisher
Aug 27, 2026

FDA grants fast track status to CytomX’s colorectal cancer drug - Investing.com

Aug 27, 2026
pulisher
Aug 27, 2026

FDA grants fast track status to CytomX’s colorectal cancer drug By Investing.com - Investing.com UK

Aug 27, 2026
pulisher
Aug 27, 2026

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - finance.yahoo.com

Aug 27, 2026
pulisher
Aug 27, 2026

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ('Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - The Manila Times

Aug 27, 2026
pulisher
Aug 27, 2026

FDA Fast Track status comes as CytomX plans a 2027 colorectal cancer study - Stock Titan

Aug 27, 2026
pulisher
Aug 24, 2026

CytomX (CTMX) Stock: Ends Up by 1.37% at $3.33 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateVanna Flow - siam.in

Aug 24, 2026
pulisher
Aug 24, 2026

CytomX (CTMX) Stock: Ends Up by 1.37% at $3.33 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateProfit Surge Picks - vinanet.vn

Aug 24, 2026
pulisher
Aug 21, 2026

CytomX Therapeutics (NASDAQ:CTMX) Downgraded to "Hold" Rating by Zacks Research - MarketBeat

Aug 21, 2026
pulisher
Aug 17, 2026

CytomX Therapeutics (CTMX) Climbs 2.68% to $3.45, Trades Within Key Support-Resistance RangeHidden Order - vinanet.vn

Aug 17, 2026
pulisher
Aug 15, 2026

CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Aug 15, 2026
pulisher
Aug 14, 2026

Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

CytomX Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | CTMX | US23284F1057 - marketscreener.com

Aug 14, 2026
pulisher
Aug 13, 2026

CTMX Maintained by JP Morgan -- Price Target Lowered to $11.00 - GuruFocus

Aug 13, 2026
pulisher
Aug 13, 2026

CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Aug 13, 2026
pulisher
Aug 13, 2026

CytomX Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo

Aug 13, 2026
pulisher
Aug 13, 2026

Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX - marketbeat.com

Aug 13, 2026
pulisher
Aug 13, 2026

MSN Money - MSN

Aug 13, 2026
pulisher
Aug 12, 2026

CytomX Therapeutics: Promising Varseta-M With Comfortable Runway (NASDAQ:CTMX) - Seeking Alpha

Aug 12, 2026
pulisher
Aug 12, 2026

CytomX upgrades to speculative Buy on promising cancer drug Varseta-M and expanded Regeneron partnership - Pluang

Aug 12, 2026
pulisher
Aug 10, 2026

CTMX Maintained by Guggenheim -- Price Target Lowered to $14.00 - GuruFocus

Aug 10, 2026
pulisher
Aug 10, 2026

Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com South Africa

Aug 10, 2026
pulisher
Aug 10, 2026

Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com Australia

Aug 10, 2026
pulisher
Aug 10, 2026

Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com Nigeria

Aug 10, 2026
pulisher
Aug 10, 2026

Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com

Aug 10, 2026
pulisher
Aug 10, 2026

Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com Canada

Aug 10, 2026
pulisher
Aug 10, 2026

Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com India

Aug 10, 2026
pulisher
Aug 10, 2026

Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com UK

Aug 10, 2026
pulisher
Aug 10, 2026

CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP - MarketBeat

Aug 10, 2026
pulisher
Aug 09, 2026

Q2 2026 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus

Aug 09, 2026
pulisher
Aug 09, 2026

Q4 2025 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus

Aug 09, 2026
pulisher
Aug 08, 2026

Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX), Cytokinetics (CYTK) and Scholar Rock Holding (SRRK) - The Globe and Mail

Aug 08, 2026

Cytomx Therapeutics Inc (CTMX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Cytomx Therapeutics Inc (CTMX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Chu Yu-Waye
Chief Medical Officer
Mar 17 '26
Sale
6.42
21,279
136,675
189,446
McCarthy Sean A.
CEO
Mar 17 '26
Sale
6.42
118,969
764,138
1,078,922
BELVIN MARCIA
SVP, Chief Scientific Officer
Mar 17 '26
Sale
6.42
31,492
202,273
300,760
Ogden Christopher
Chief Financial Officer
Mar 17 '26
Sale
6.42
19,323
124,112
296,948
McCarthy Sean A.
CEO
Nov 06 '25
Sale
4.54
101,793
461,906
987,891
Sean McCarthy
CEO
Nov 06 '25
Proposed Sale
4.54
101,793
461,909
0
$10.31
price down icon 4.80%
$18.15
price down icon 7.82%
$3.32
price down icon 8.03%
$9.78
price down icon 10.36%
$7.02
price down icon 4.62%
$10.39
price down icon 8.22%
大文字化:     |  ボリューム (24 時間):